Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Historical cardiovascular-outcome and indication limitations are not a current evidence review.
Check source scope before reading a dose
GlobalRPh RX List - ZYPITAMAG
Product / population
Adult pitavastatin with ZYPITAMAG-specific strength limitation.
Renal method
Indexed eGFR, mL/min/1.73 m2; ESRD on hemodialysis.
Source revision
Source revision date not established in selected retrieval.
Retrieved
2026-09-07
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
A labeled starting amount may not exist in this brand
The renal starting amount is lower than the available ZYPITAMAG strengths. The source directs use of another pitavastatin formulation.
What to reconcile: Verify the dispensed formulation and strength; do not invent a splitting instruction or start at the renal maximum merely because that strength is available.
GlobalRPh-hosted RX List · Adult pitavastatin with ZYPITAMAG-specific strength limitation.
Renal method: Indexed eGFR, mL/min/1.73 m2; ESRD on hemodialysis. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
For indexed eGFR 15-59 mL/min/1.73 m2 or end-stage disease receiving hemodialysis, start pitavastatin 1 mg once daily and do not exceed 2 mg daily. ZYPITAMAG is not available as a 1 mg tablet: use a different pitavastatin formulation for that starting dose, rather than inventing a tablet-splitting instruction. Mild renal impairment has no specific adjustment recommendation in this source.
RDM37-rxlist-pitavastatin-d0a53d92aa-C1 · Source locator: Dosage: Recommended Dosage in Patients With Renal Impairment.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.